AGL 40.00 No Change ▼ 0.00 (0%)
AIRLINK 129.00 Decreased By ▼ -0.53 (-0.41%)
BOP 6.76 Increased By ▲ 0.08 (1.2%)
CNERGY 4.50 Decreased By ▼ -0.13 (-2.81%)
DCL 8.70 Decreased By ▼ -0.24 (-2.68%)
DFML 41.00 Decreased By ▼ -0.69 (-1.66%)
DGKC 81.30 Decreased By ▼ -2.47 (-2.95%)
FCCL 32.68 Decreased By ▼ -0.09 (-0.27%)
FFBL 74.25 Decreased By ▼ -1.22 (-1.62%)
FFL 11.75 Increased By ▲ 0.28 (2.44%)
HUBC 110.03 Decreased By ▼ -0.52 (-0.47%)
HUMNL 13.80 Decreased By ▼ -0.76 (-5.22%)
KEL 5.29 Decreased By ▼ -0.10 (-1.86%)
KOSM 7.63 Decreased By ▼ -0.77 (-9.17%)
MLCF 38.35 Decreased By ▼ -1.44 (-3.62%)
NBP 63.70 Increased By ▲ 3.41 (5.66%)
OGDC 194.88 Decreased By ▼ -4.78 (-2.39%)
PAEL 25.75 Decreased By ▼ -0.90 (-3.38%)
PIBTL 7.37 Decreased By ▼ -0.29 (-3.79%)
PPL 155.74 Decreased By ▼ -2.18 (-1.38%)
PRL 25.70 Decreased By ▼ -1.03 (-3.85%)
PTC 17.56 Decreased By ▼ -0.90 (-4.88%)
SEARL 78.71 Decreased By ▼ -3.73 (-4.52%)
TELE 7.88 Decreased By ▼ -0.43 (-5.17%)
TOMCL 33.61 Decreased By ▼ -0.90 (-2.61%)
TPLP 8.41 Decreased By ▼ -0.65 (-7.17%)
TREET 16.26 Decreased By ▼ -1.21 (-6.93%)
TRG 58.60 Decreased By ▼ -2.72 (-4.44%)
UNITY 27.51 Increased By ▲ 0.08 (0.29%)
WTL 1.41 Increased By ▲ 0.03 (2.17%)
BR100 10,450 Increased By 43.4 (0.42%)
BR30 31,209 Decreased By -504.2 (-1.59%)
KSE100 97,798 Increased By 469.8 (0.48%)
KSE30 30,481 Increased By 288.3 (0.95%)
World

WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients

  • These therapies - artesunate, imatinib and infliximab - were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients
Published August 11, 2021

ZURICH: The World Health Organization (WHO) said on Wednesday a clinical trial in 52 countries would study three anti-inflammatory drugs as potential treatments for COVID-19 patients.

"These therapies - artesunate, imatinib and infliximab - were selected by an independent expert panel for their potential in reducing the risk of death in hospitalised COVID-19 patients," it said in a statement on the Solidarity PLUS trial.

Artesunate is already used for severe malaria, imatinib for certain cancers, and infliximab for diseases of the immune system such as Crohn's Disease and rheumatoid arthritis.

The original Solidarity trial last year found that all four treatments evaluated - remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon - had little or no effect in helping COVID patients.

So far, only corticosteroids have been proven effective against severe and critical COVID-19.

Antibodies from Sinovac's Covid-19 shot fade after about 6 months, booster helps: study

The WHO said artesunate, produced by Ipca, is used to treat malaria. In the trial, it will be administered intravenously for seven days, using the standard dose recommended for the treatment of severe malaria.

Imatinib, produced by Novartis, is used to treat certain cancers. In the trial, it will be administered orally, once daily, for 14 days.

Infliximab, produced by Johnson and Johnson, is used to treat diseases of the immune system. In the trial, it will be administered intravenously as a single dose.

Comments

Comments are closed.